Minimed Paradigm

Ascensia Diabetes Care Launches Patient Assistance Program To Provide Broader Access To Eversense Continuous Glucose Monitoring System

Retrieved on: 
Tuesday, July 20, 2021
Medicine, Diabetes, Clinical medicine, Medical equipment, Medical monitoring, Continuous glucose monitor, Blood glucose monitoring, Diabetes management, Type 1 diabetes, Minimed Paradigm, Ambulatory glucose profile

PARSIPPANY, N.J., July 20, 2021 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes company, announced it has introduced a Patient Assistance Program in the United States to reduce out-of-pocket costs associated with the Eversense Continuous Glucose Monitoring (CGM) System.

Key Points: 
  • PARSIPPANY, N.J., July 20, 2021 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes company, announced it has introduced a Patient Assistance Program in the United States to reduce out-of-pocket costs associated with the Eversense Continuous Glucose Monitoring (CGM) System.
  • Overall, the Program has the potential to save eligible Eversense users up to $1,200 per year on their cumulative 90-day sensor out-of-pocket costs.
  • Our goal is to make Eversense more affordable and provide improved access to this unique and innovative diabetes management technology."
  • Slattery D, Choudhary P. Clinical Use of Continuous Glucose Monitoring in Adults with Type 1 Diabetes.

Senseonics Announces Presentation of PROMISE Data at the American Diabetes Association 81st Scientific Sessions

Retrieved on: 
Monday, June 28, 2021
Research, Mobile, Wireless, Technology, Medical devices, Diabetes, Clinical trials, Software, Hardware, Health, Science, Diabetes, Medicine, Medical equipment, Medical technology, Medical monitoring, Continuous glucose monitor, Blood glucose monitoring, Diabetes management, Blood tests, CGM, Blood sugar level, Minimed Paradigm, Eversense, Senseonics, EVERSENSE, SENSEONICS

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced further presentation of PROMISE Study data evaluating the next generation Eversense CGM System at the American Diabetes Association Virtual 81st Annual Scientific Sessions.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced further presentation of PROMISE Study data evaluating the next generation Eversense CGM System at the American Diabetes Association Virtual 81st Annual Scientific Sessions.
  • The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions in the US.
  • The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more.
  • The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Roche Diabetes Care Canada Receives Health Canada Authorization for the Accu-Chek® Guide Link Blood Glucose Meter with Wireless Connectivity

Retrieved on: 
Monday, June 14, 2021
Medicine, Clinical medicine, Diabetes, Health, Glucose meter, Insulin pump, Type 1 diabetes, Insulin, Book:Diabetes medical equipment, Minimed Paradigm

Through an agreement between Roche Diabetes Care and Medtronic Canada, the Accu-Chek Guide Link is a state-of-the-art blood glucose meter designed to connect exclusively to the Medtronic MiniMedTM 770G insulin pump system.

Key Points: 
  • Through an agreement between Roche Diabetes Care and Medtronic Canada, the Accu-Chek Guide Link is a state-of-the-art blood glucose meter designed to connect exclusively to the Medtronic MiniMedTM 770G insulin pump system.
  • LAVAL, QC, June 14, 2021 /CNW/ - Roche Diabetes Care Canada is pleased to announce that it has received a Health Canada authorization for the Accu-Chek Guide Link blood glucose meter, the latest innovation from Roche Diabetes Care to help Canadians living with type-1 diabetes manage their health and worry less about daily therapy routines.
  • "At Roche Diabetes Care, our vision is to help people with diabetes think less about their daily diabetes routine so they can focus more on life.
  • Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures.

Germany Diabetes Market Report 2020-2025: Market is Expected to be $12 Billion - Lifestyle-Compatible Treatment Options and Technological Advancement in Insulin Pump Devices

Retrieved on: 
Monday, March 29, 2021
Medicine, Clinical medicine, Diabetes, Medical monitoring, Blood glucose monitoring, Insulin pump, Insulin, Continuous glucose monitor, Diabetes management, Minimed Paradigm

DUBLIN, March 29, 2021 /PRNewswire/ -- The "Germany Diabetes Market, by Continuous Glucose Monitoring (CGM), Blood Glucose (SMBG) Device, Insulin Pen, Insulin Pump, Reimbursement Company Analysis & Forecast" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 29, 2021 /PRNewswire/ -- The "Germany Diabetes Market, by Continuous Glucose Monitoring (CGM), Blood Glucose (SMBG) Device, Insulin Pen, Insulin Pump, Reimbursement Company Analysis & Forecast" report has been added to ResearchAndMarkets.com's offering.
  • Germany Diabetes Market is expected to be USD 12 Billion by the end of the year 2025.
  • Diabetes mellitus is a significant public health problem and one of the biggest challenges for healthcare systems all over Germany.
  • In this report, Germany Diabetic market is segmented into four parts; Insulin Pen, CGM, SMBG, and Insulin Pump.

Insulet’s Omnipod® 5 Automated Insulin Delivery System Improves Clinical Outcomes in Type 1 Diabetes

Retrieved on: 
Saturday, March 20, 2021
Diabetes, Health, Medical devices, Clinical medicine, Medicine, Organ systems, Diabetes, Insulin pump, Peptide hormones, Recombinant proteins, Diabetes management, Insulin, Type 1 diabetes, Dexcom, Minimed Paradigm

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced positive results from the first pivotal trial for the Omnipod 5 Automated Insulin Delivery System.

Key Points: 
  • Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced positive results from the first pivotal trial for the Omnipod 5 Automated Insulin Delivery System.
  • Omnipod 5, the worlds first tubeless, wearable system that continuously adapts insulin delivery based on glucose levels and trends, significantly improved time in range and reduced HbA1c in children, adolescents, and adults, aged 6-70 years, with type 1 diabetes.
  • The Omnipod 5 System is phenomenal, improving diabetes outcomes for children and adults while greatly reducing the burden of diabetes management, said Dr. Forlenza.
  • The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods.

Netherlands Diabetes Market Report 2020: Blood Glucose (SMBG) Device, Continuous Glucose Monitoring (CGM), Insulin Pen, Insulin Pump, Reimbursement Company Analysis & Forecast to 2025

Retrieved on: 
Friday, March 19, 2021
Medicine, Diabetes, Clinical medicine, Medical monitoring, Blood glucose monitoring, Insulin pump, Insulin, Continuous glucose monitor, Type 1 diabetes, Diabetes management, Minimed Paradigm

DUBLIN, March 19, 2021 /PRNewswire/ -- The "The Netherlands Diabetes Market, by Blood Glucose (SMBG) Device, Continuous Glucose Monitoring (CGM), Insulin Pen, Insulin Pump, Reimbursement Company Analysis & Forecast" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 19, 2021 /PRNewswire/ -- The "The Netherlands Diabetes Market, by Blood Glucose (SMBG) Device, Continuous Glucose Monitoring (CGM), Insulin Pen, Insulin Pump, Reimbursement Company Analysis & Forecast" report has been added to ResearchAndMarkets.com's offering.
  • Netherlands Diabetes Market is gardened to reach USD 4.48 Billion by the year 2025.
  • DM (diabetes mellitus) care and its provision will continue to play an important role in health care in The Netherlands.
  • The market of Continuous Glucose Monitoring (CGM) Device, Self Monitoring Blood Glucose Device, Insulin Pen, and Insulin Pump are growing due to the rising awareness for diabetes in Netherland.

Diabeloop integrates the Accu-Chek Insight insulin pump from Roche into its Automated Insulin Delivery System

Retrieved on: 
Monday, March 1, 2021
Medical equipment, Clinical medicine, Medicine, Insulin pump, Insulin, Glucose meter, Book:Diabetes medical equipment, Minimed Paradigm

/PRNewswire/ -- DBLG1 System, the AID (Automated Insulin Delivery) system from Diabeloop individualizes treatment by automating insulin decisions.

Key Points: 
  • /PRNewswire/ -- DBLG1 System, the AID (Automated Insulin Delivery) system from Diabeloop individualizes treatment by automating insulin decisions.
  • PARIS, March 1, 2021 With the integration of the Accu-Chek Insight insulin pump, Diabeloop and Roche offer people with diabetes the possibility to choose an automated and personalized management using a sleek-designed and pre-filled insulin cartridge pump.
  • The Accu-Chek Insight insulin pump will be the first pump with a pre-filled cartridge that can be operated in hybrid-closed loop mode," said Marcel Gmuender, Head of Roche Diabetes Care.
  • In early 2021, Accu-Chek Insight users in Germany, Italy, Spain, Switzerland, and the Netherlands will be able to operate the insulin pump in loop mode, within the DBLG1 System with Accu-Chek Insight insulin pump.

Independent Study by Actuarial Firm Finds Paradigm Catastrophic Care Management's Improved Outcomes Managing Workers' Compensation Claims

Retrieved on: 
Tuesday, December 1, 2020
Articles, Aesthetics, Consensus reality, Epistemology of science, Paradigm, Branches of philosophy, Health informatics, Epistemology, Health care management, Minimed Paradigm

It consistently found improved cost and clinical outcomes compared to conventional case management industry standards.

Key Points: 
  • It consistently found improved cost and clinical outcomes compared to conventional case management industry standards.
  • The study compared 593 Paradigm cases completed since 2013 against the projected industry outcomes without Paradigm intervention.
  • For almost 30 years, Paradigm has been the industry leader in solving catastrophic and complex health care challenges and improving lives.
  • Paradigm delivers its solutions through three divisions: Catastrophic Care Management, Complex Care Solutions, and Specialty Networks.

Diabetes Drug Delivery Devices Market, 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 27, 2020
Diabetes, Health, Medical devices, Medicine, Medical technology, Clinical medicine, Medical equipment, Insulin, Autoinjector, Jet injector, Diabetes, Diabetes management, Minimed Paradigm

The "Diabetes Drug Delivery Devices Market, 2020-2030" report features an extensive study of the current market landscape and the likely adoption of diabetes drug delivery devices, over the next decade.

Key Points: 
  • The "Diabetes Drug Delivery Devices Market, 2020-2030" report features an extensive study of the current market landscape and the likely adoption of diabetes drug delivery devices, over the next decade.
  • One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for diabetes drug delivery devices.
  • An overview of the current market landscape of diabetes drug delivery devices available for delivery of insulin and non-insulin drugs, including information on device specifications, such as type of device (insulin pump, pen-injector/autoinjector, jet injector, microneedle patch, nasal delivery system, insulin port, oral delivery system and inhalation device), stage of development (marketed, clinical and preclinical), route of administration (subcutaneous, intramuscular, transdermal, oral, intranasal and others), mode of drug delivery (invasive, minimally invasive and non-invasive), needle attributes (needleless, detachable needle, cannula, hidden needle and fixed needle), type of drug delivery system (mechanical method and electrical method), drug administration speed (fast and slow), device usability (disposable, reusable and reusable (disposable components)), diabetes type (type I diabetes, type II diabetes and diabetes type (unspecified)) and type of drug (insulin and non-insulin).
  • A detailed competitiveness analysis of diabetes drug delivery devices based on various relevant parameters, such as supplier power (based on the experience/expertise of the developer) and product specifications (type of device, route of administration, diabetes type, needle attributes, availability of needle safety system, self-administration potential, mode of drug delivery, device usability, drug administration speed and development stage).

Continuous Glucose Monitoring Device Market Size is Predicted to Reach $12.18 Billion By 2026 | CAGR: 15.8%: Polaris Market Research

Retrieved on: 
Tuesday, November 24, 2020
Medicine, Medical specialties, Clinical medicine, Medical monitoring, Continuous glucose monitor, Blood glucose monitoring, CGM, Diabetes, Monitoring, Glucose, Dexcom, Minimed Paradigm

Additionally, growing awareness regarding the use of CGM devices in developing countries as well as the untapped market is anticipated to create lucrative opportunities within the market.

Key Points: 
  • Additionally, growing awareness regarding the use of CGM devices in developing countries as well as the untapped market is anticipated to create lucrative opportunities within the market.
  • Continuous research and development activities to reduce procedural costs are projected to further fuel the growth of the global continuous glucose monitoring market.
  • The segment is expected to register a major growth with a surge in demand for CGM devices for efficient monitoring of blood glucose.
  • To get Discounts on this Premium Report, Click At : https://www.polarismarketresearch.com/industry-analysis/continuous-gluco...
    Polaris Market research has segmented the Continuous Glucose Monitoring Device Market report on the basis of component type, end-use and region:
    Continuous Glucose Monitoring Device component type Outlook (Revenue, USD Million, 2015 2026)